Mayo Clinic January 14, 2025
John Halamka

Mayo Clinic’s Tapestry Study has demonstrated that next generation genetic analysis can have a significant impact on patient care.

By John Halamka, M.D., President, Mayo Clinic Platform and Paul Cerrato, MA, senior research analyst and communications specialist, Mayo Clinic Platform

On April 14, 2003, the world learned that the Human Genome Project had been completed. As the National Institutes of Health pointed out, it was one of the greatest scientific accomplishments in history and the first completed sequence of the human genome, the DNA that determines not only the color of our eyes, but our susceptibility to many diseases. Unfortunately, many clinicians were disappointed when they realized the data didn’t have an immediate effect on routine patient care. Why...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

 
Topics: Clinical Trials, Health System / Hospital, Pharma / Biotech, Precision Medicine, Provider, Trends
JPM 2026: Genoa Ventures’ Jenny Rooke on Next-Gen Clinical Assessment Tools
From Early Detection to Targeted Therapy: How AI is Reframing Precision Medicine
How Precision Medicine and AI are Evolving: An MD Anderson Perspective
Bringing Precision Medicine Into the Home
Inside the Virtual Cell: New Depths for Precision Medicine

Share Article